These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 34024681

  • 1. Perspective - The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021.
    Di Minno A, Spadarella G, Esposito S, Mathew P, Di Minno G, Mannucci PM.
    Blood Rev; 2021 Nov; 50():100849. PubMed ID: 34024681
    [Abstract] [Full Text] [Related]

  • 2. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A, Moonla C, Sosothikul D.
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [Abstract] [Full Text] [Related]

  • 3. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
    Nummi V, Lehtinen AE, Iorio A, Szanto T, Lassila R.
    Haemophilia; 2022 Nov; 28(6):e237-e244. PubMed ID: 35939628
    [Abstract] [Full Text] [Related]

  • 4. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD, Chelle P, Clarke E, Kim L, Tiseo L, Morfini M, Hossain T, Rand ML, Brown C, Edginton AN, Lillicrap D, Iorio A, Blanchette VS.
    J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
    [Abstract] [Full Text] [Related]

  • 5. Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia.
    Turecek PL, Johnsen JM, Pipe SW, O'Donnell JS, iPATH study group.
    Haemophilia; 2020 Jul; 26(4):575-583. PubMed ID: 32596930
    [Abstract] [Full Text] [Related]

  • 6. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE.
    Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
    [Abstract] [Full Text] [Related]

  • 7. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.
    Elsheikh E, Lavin M, Heck LA, Larkin N, Mullaney B, Doherty D, Kennedy M, Keenan C, Guest T, O'Mahony B, Fazavana J, Fallon PG, Preston RJS, Gormley J, Ryan K, O'Connell NM, Singleton E, Byrne M, McGowan M, Roche S, Doyle M, Crowley MP, O'Shea SI, Reipert BM, Johnsen JM, Pipe SW, Di Paola J, Turecek PL, O'Donnell JS, iPATH study group.
    J Thromb Haemost; 2023 May; 21(5):1123-1134. PubMed ID: 36775768
    [Abstract] [Full Text] [Related]

  • 8. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis.
    Srichumpuang C, Rakmanotham A, Moonla C, Sosothikul D.
    Orphanet J Rare Dis; 2024 Mar 26; 19(1):135. PubMed ID: 38532451
    [Abstract] [Full Text] [Related]

  • 9. Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A.
    Konkle BA.
    Expert Rev Hematol; 2023 Mar 26; 16(8):567-573. PubMed ID: 37289594
    [Abstract] [Full Text] [Related]

  • 10. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients.
    Yu JK, Iorio A, Edginton AN.
    Thromb Res; 2020 Dec 26; 196():550-558. PubMed ID: 33157394
    [Abstract] [Full Text] [Related]

  • 11. Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.
    Tagliaferri A, Matichecchia A, Rivolta GF, Riccardi F, Quintavalle G, Benegiamo A, Rossi R, Coppola A.
    Blood Transfus; 2020 Sep 26; 18(5):374-385. PubMed ID: 31855153
    [Abstract] [Full Text] [Related]

  • 12. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.
    Swystun LL, Ogiwara K, Rawley O, Brown C, Georgescu I, Hopman W, Labarque V, Male C, Thom K, Blanchette VS, Carcao MD, Lillicrap D.
    Blood; 2019 Sep 12; 134(11):880-891. PubMed ID: 31350267
    [Abstract] [Full Text] [Related]

  • 13. Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats.
    Vargas Christensen I, Loftager M, Rode F, Mørck Nielsen H, Kreilgaard M, Larsen MS.
    J Thromb Haemost; 2019 Jun 12; 17(6):964-974. PubMed ID: 30924607
    [Abstract] [Full Text] [Related]

  • 14. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.
    Lalezari S, Martinowitz U, Windyga J, Enriquez MM, Delesen H, Schwartz L, Scharrer I.
    Haemophilia; 2014 Jan 12; 20(1):e15-22. PubMed ID: 24252058
    [Abstract] [Full Text] [Related]

  • 15. Modulation of factor VIII pharmacokinetics by genetic components in factor VIII receptors.
    Lunghi B, Morfini M, Martinelli N, Branchini A, Linari S, Castaman G, Bernardi F.
    Haemophilia; 2023 Mar 12; 29(2):479-487. PubMed ID: 36533781
    [Abstract] [Full Text] [Related]

  • 16. No immunological changes after factor VIII product switch: An in depth analysis in haemophilia A patients.
    Schep SJ, Fischer K, Boes M, Schutgens REG.
    Haemophilia; 2023 Jul 12; 29(4):1039-1048. PubMed ID: 37276354
    [Abstract] [Full Text] [Related]

  • 17. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
    Zourikian N, Merlen C, Bonnefoy A, St-Louis J, Rivard GE.
    Haemophilia; 2016 May 12; 22(3):e177-83. PubMed ID: 26988074
    [Abstract] [Full Text] [Related]

  • 18. Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice.
    Sarafanov AG.
    Int J Mol Sci; 2023 May 11; 24(10):. PubMed ID: 37239930
    [Abstract] [Full Text] [Related]

  • 19. Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients.
    Megías-Vericat JE, Bonanad S, Haya S, Cid AR, Marqués MR, Ferrada A, Monte-Boquet E, Pérez-Alenda S, Bosch P, Querol-Giner F, Poveda JL.
    Thromb Res; 2021 Sep 11; 205():99-105. PubMed ID: 34293540
    [Abstract] [Full Text] [Related]

  • 20. Recombinant factor VIII: past, present and future of treatment of hemophilia A.
    Raso S, Hermans C.
    Drugs Today (Barc); 2018 Apr 11; 54(4):269-281. PubMed ID: 29869648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.